Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000287690 | SCV000344590 | uncertain significance | not provided | 2017-11-14 | criteria provided, single submitter | clinical testing | |
Genomic Research Center, |
RCV004549620 | SCV000930329 | uncertain significance | DYSF-related disorder | 2019-04-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001062505 | SCV001227311 | benign | Qualitative or quantitative defects of dysferlin | 2024-11-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002518115 | SCV003575145 | uncertain significance | Inborn genetic diseases | 2021-08-02 | criteria provided, single submitter | clinical testing | The c.4757G>A (p.R1586Q) alteration is located in exon 43 (coding exon 43) of the DYSF gene. This alteration results from a G to A substitution at nucleotide position 4757, causing the arginine (R) at amino acid position 1586 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000287690 | SCV003830845 | uncertain significance | not provided | 2020-11-16 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001271546 | SCV001452781 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2020-09-16 | no assertion criteria provided | clinical testing |